

## Special Issue

# Editorial Board Members' Collection Series: "Amyotrophic Lateral Sclerosis: The Present and the Future of the Research"

### Message from the Guest Editors

This Special Issue gathers a team of experts, both clinicians and basic scientists, to provide a comprehensive update of Amyotrophic Lateral Sclerosis (ALS). ALS is a fatal and incurable neurodegenerative disease that targets motor neurons, leading to the complete paralysis of all voluntary muscles and death due to respiratory failure within 2-5 years from the onset. Research in this field has greatly advanced in the last few decades. In this Special Issue, the authors present recent results that offer new insights into various perspectives of the disease from genetic and pathogenetic findings toward diagnosis and prognostic and diagnostic Biomarkers. Moreover, a dedicated session will focus on new insights into the development of advanced therapies for personalized treatments to cure or prevent this devastating disease.

### Guest Editors

Prof. Dr. Letizia Mazzini

ALS Center Department of Neurology "Maggiore della Carità" Hospital and University of Piemonte Orientale, 28100 Novara, Italy

Dr. Tommaso Bocci

Department of Health Science, University of Milan, 20122 Milano, Italy

### Deadline for manuscript submissions

closed (31 October 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/142515](https://mdpi.com/si/142515)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).